INTRODUCTION

	Optimal Cancer Care Across the Spectrum of Life and Disease
	Gary H. Lyman, MD, MPH, FRCP(Edin); and Robert S. Hauser, PharmD, PhD The Guest Editors set the context for this special collection of oncology-focused articles. Full Text : PDF

MANAGERIAL

	Cancer Screening Across the Aging Continuum
	Barbara Resnick, PhD, CRNP; and Sandra W. McLeskey, PhD, RN The article reviews the current state of knowledge regarding screening guidelines for older adults and gives recommendations for healthcare providers working with older adults. Abstract : Full Text : PDF
	The Effect of HEDIS Measurement of Colorectal Cancer Screening on Insurance Plans in Pennsylvania
	Mona Sarfaty, MD; and Ronald E. Myers, PhD In 2006, the NCQA began reporting colorectal cancer screening rates of member plans as a HEDIS measure, which is associated with Pennsylvania health system charges. Abstract : Full Text : PDF

CLINICAL

	Managed Care and Cancer Outcomes for Medicare Beneficiaries With Disabilities
	Richard G. Roetzheim, MD, MSPH; Thomas N. Chirikos, PhD; Kristen J. Wells, PhD, MPH; Ellen P. McCarthy, PhD, MPH; Long H. Ngo, PhD; Donglin Li, MD, MPH; Reed E. Drews, MD; and Lisa I. Iezzoni, MD, MSc This study showed better outcomes for disabled Medicare patients with breast cancer but not those with lung cancer when they were enrolled in HMOs. Abstract : Full Text : Appendix : PDF

POLICY

	Second-line and Third-line Chemotherapy for Lung Cancer: Use and Cost
	Scott D. Ramsey, MD, PhD; Renato G. Martins, MD; David K. Blough, PhD; Lauri S. Tock, MHA; Deborah Lubeck, PhD; and Carolina M. Reyes, PhD Using health insurance claims, we identified common first-, second-, and third-line chemotherapy regimens for patients with lung cancer and associated utilization and costs of care. Abstract : Full Text : PDF

MANAGERIAL

	No Time to Waste: Decreasing Patient Wait Times for Chemotherapy Administration Using Automated Prioritization in an Oncology Pharmacy System
	Hanan J. Aboumatar, MD, MPH; Laura E. Winner, MBA, RN; Richard O. Davis, PhD; Peter B. Trovitch, PharmD; Maureen M. Berg, RN, OCN; Katherina M. Violette, BSN, RN; Wells A. Messersmith, MD; Karen K. Maylor, RN; and Christoph U. Lehmann, MD Using a prioritization algorithm in an oncology pharmacy system at the Johns Hopkins University, patient wait times for chemotherapy administration were significantly decreased. Abstract : Full Text : PDF

CLINICAL

	The Cost of Treating Skeletal-Related Events in Patients With Prostate Cancer
	Maureen J. Lage, PhD; Beth L. Barber, PhD; David J. Harrison, PhD; and Sun Jun, MD, PhD The analysis examines the annual economic effect of medically treating patients with prostate cancer and subsequent bone metastases. Abstract : Full Text : PDF
	Complementary and Alternative Medicine Provider Use and Expenditures by Cancer Treatment Phase
	William E. Lafferty, MD; Patrick T. Tyree, AA; Sean M. Devlin, MA; M. Robyn Andersen, PhD, MPH; and Paula K. Diehr, PhD More than 26% of cancer patients see CAM providers, primarily for musculoskeletal problems; use does not vary by treatment phase, and associated expenditures are low. Abstract : Full Text : PDF : Appendix

LIST OF PEER REVIEWERS

	List of Peer Reviewers (2007)
	Full Text :

LETTERS TO THE EDITORS

	Is Disease Management Effective? Well...Some is.
	Robert E. Stone, MBA Full Text : Web Exclusive

April 08 - Management and Pharmacoeconomics of Dry Eye Disease: The Role of Cyclosporine

March 08 - Parkinson’s Disease: Quality Assessment and Improvement of Care

February 08 - Managed Care Issues in Glaucoma: Emerging Trends and Treatment

December 07 - Health-related Quality of Life in Rheumatoid Arthritis